Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

330 Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M et al. The protective
effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Arthritis Rheum 2010; 62: 863–868.
331 Sabio J, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J, Rodríguez
del Águila M. Metabolic syndrome in patients with systemic lupus erythematosus from
Southern Spain. Lupus 2008; 17: 849–859.
332 Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C et al. Impact of early
disease factors on metabolic syndrome in systemic lupus erythematosus: data from an
international inception cohort. Ann Rheum Dis 2014; : 1–7.
333 Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide M-V,
Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res
Ther 2009; 11: R109.
334 Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to
antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch
Dermatol 2011; 147: 1261–1267.
335 Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P et
al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features
and follow-up of 148 patients. Clin Exp Rheymatology 2001; 17: 403–409.
336 Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan T. The benefit of combining
hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9: 92–
95.
337 Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in
patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res
(Hoboken) 2010; 62: 775–784.
338 Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on
screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118:
415–422.
339 Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE.
Rheumatology (Oxford) 2012; 51: 1145–1153.
340 Buttgereit F, Burmester G-R, Lipworth BJ. Optimised glucocorticoid therapy: the
sharpening of an old spear. Lancet 2005; 365: 801–803.
341 Buttgereit F, Straub RH, Wehling M, Burmester G-R. Glucocorticoids in the treatment of
rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50:
3408–3417.
342 Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I et al. Efficacy and safety of entericcoated
mycophenolate sodium in combination with two glucocorticoid regimens for the
treatment of active lupus nephritis. Lupus 2011; 20: 1484–1493.
343 Yee C-S, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B et al. EULAR
randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus
460 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS